Solar Energy News  
China To Make Cuban Dengue Mosquito Killer

The Aedes aegypti mosquito likewise causes 200,000 cases of yellow fever a year, resulting in 30,000 deaths, 95 percent of them in Africa.
by Staff Writers
Havana, Cuba (AFP) Jul 24, 2007
China will mass-produce a Cuban pesticide effective against dengue-carrying mosquitos, Cuba's foreign ministry said Sunday. Cuban scientists developed and patented Bactivec, a biolarvicide which kills larvae of the Aedes aegypti mosquito, the dengue vector, the ministry statement said.

According to the agreement, China will defray the cost of building the factory in China, and Cuban Labiofam scientists will provide the technology and know-how to build it.

Cuba will purchase six million units annually of the insecticide, and China will donate another half million to Cuba, the statement said.

Cuba suffered four dengue outbreaks during 1977-2002. In the most recent outbreak 14,524 cases were reported between June 2001 and March 2002, including 81 cases of dengue haemorrhagic fever, three of which were fatal.

Dengue fever has is found in the tropics throughout the world, and the World Health Organization estimates there could be some 50 million cases each year, and 500,000 cases of more dangerous dengue haemorrhagic fever.

The Aedes aegypti mosquito likewise causes 200,000 cases of yellow fever a year, resulting in 30,000 deaths, 95 percent of them in Africa.

Cuba, the only country that produces Bactivec, struck a similar deal in 2000 with Amazonas state in Brazil, which produces and sells the biolarvicide to other countries.

Source: Agence France-Presse

Related Links
Epidemics on Earth - Bird Flu, HIV/AIDS, Ebola



Memory Foam Mattress Review
Newsletters :: SpaceDaily :: SpaceWar :: TerraDaily :: Energy Daily
XML Feeds :: Space News :: Earth News :: War News :: Solar Energy News


Tibotec HIV Drug Shows Promise
Washington (UPI) Jul 05, 2007
Tibotec's HIV drug, TMC125, may be better at fighting resistant strains of the virus than current medications, according to two phase 3 trials released Thursday. In the trials, known as DUET-1 and DUET-2, TMC125, a non-nucleoside reverse transcriptase inhibitor, or NNRTI, suppressed virus levels better than placebo in patients who had previously been treated with other medications and had developed resistance.







  • Constellation Energy And EDF Form Joint Venture For Next-Generation Nuclear Facilities
  • Russia Opens The Door To Foreign Nuclear Investment And Technology
  • Algae The Misunderstood Answer To Our Fuel And Global Warming Problems
  • UN To Inspect Japan Radiation Site

  • New Study Suggests Climate Change Could Be The Root Of Armed Conflicts
  • Western US States Swelter Under Record Heatwave
  • The Challenge Of Desertification
  • Australian Drought Turns To Flood As California Dries Out

  • NASA Researchers Find Satellite Data Can Warn Of Famine
  • Eat A Steak, Warm The Planet
  • Organic Farming Can Feed the World
  • Simulated Crop Provides Answer To Irrigation Issues

  • Ice Age Survivors In Iceland
  • In An Evolutionary Arms Race A Bacterium Is Found That Outwits Tomato Plant's Defenses
  • Mushroom Secrets Could Combat Carbon, Enable Better Biofuels And Clean Soil
  • Bush administration accused of putting ideology above science

  • ATK Wins Another Orion Launch Abort Subsystem Contract
  • Old Space Prepares To Buy New Space As Northrop Scoops Up Scaled Composites
  • Pratt And Whitney Rocketdyne Awarded NASA Contract For J-2X Ares Rocket Engine
  • Ares Team Validates Manufacturing Processes For Common Bulkhead Demonstration



  • Envisat Captures Breath Of Volcano
  • NASA Awards Contract For Land-Imaging Instrument
  • GOP House Science Committee To Evaluate NASA Earth Science Budget
  • Subcommittee Continues Look At Status of NASA Earth Science Programs

  • Nature's Secrets Yield New Adhesive Material
  • Smart Fabric Biosensors Will Monitor Respiration Rate And Body Temperature In Real Time
  • BAE Systems To Produce Field Programmable Gate Array For Space Use
  • Researchers Develop Tool For Clearer Ultrasound Images

  • The content herein, unless otherwise known to be public domain, are Copyright Space.TV Corporation. AFP and UPI Wire Stories are copyright Agence France-Presse and United Press International. ESA Portal Reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space.TV Corp on any Web page published or hosted by Space.TV Corp. Privacy Statement